OncClubAll Oncology News
InsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid Readouts
Conference CoverageConference Listing
Giants of Cancer CareCME/CEScientific InterchangesState of the Science Summit / IPCNational Fellows ForumWebinars
PartnersPublications
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker ConsortiumSubscribe
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
Spotlight -
  • The OncLive Insider app is live!
  • CME Opportunities
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
    • Partners
    • Publications
    • Biomarker Consortium
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Treatment-Related Interstitial Lung Disease

home / insights / treatment-related-interstitial-lung-disease

Through the lens of multidisciplinary management in breast cancer, experts share practical insight on the identification and management of interstitial lung disease.

Managing Breast Cancer: Who’s Involved in Multidisciplinary Care?

EP. 1: Managing Breast Cancer: Who’s Involved in Multidisciplinary Care?

Mark Pegram, MD, Stanford Women's Cancer Center;Charles A. Powell, MD, MBA, Mount Sinai-National Jewish Health Respiratory Institute;Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center
August 25th 2021

Experts reflect on the importance of multidisciplinary care and outline the many disciplines involved in diagnosing and treating breast cancer.

Managing Breast Cancer: Collaboration Throughout the Treatment Journey

EP. 2: Managing Breast Cancer: Collaboration Throughout the Treatment Journey

Mark Pegram, MD, Stanford Women's Cancer Center;Charles A. Powell, MD, MBA, Mount Sinai-National Jewish Health Respiratory Institute;Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center
August 25th 2021

Comprehensive details on how multidisciplinary care is applied during a patient’s treatment journey, with a focus on pulmonology and critical care.

Difference in Breast Cancer Outcomes With Multidisciplinary Care

EP. 3: Difference in Breast Cancer Outcomes With Multidisciplinary Care

Mark Pegram, MD, Stanford Women's Cancer Center;Charles A. Powell, MD, MBA, Mount Sinai-National Jewish Health Respiratory Institute;Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center
September 1st 2021

Shared insight on how nuanced multidisciplinary care can positively impact outcomes when treating a patient with breast cancer.

Multidisciplinary Care in BC: How Best to Communicate Patient Information

EP. 4: Multidisciplinary Care in BC: How Best to Communicate Patient Information

Mark Pegram, MD, Stanford Women's Cancer Center;Charles A. Powell, MD, MBA, Mount Sinai-National Jewish Health Respiratory Institute;Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center
September 1st 2021

Focusing on the value of electronic systems and tumor boards, experts detail how best to communicate across disciplines in the management of breast cancer.

Challenges in the Multidisciplinary Management of Breast Cancer

EP. 5: Challenges in the Multidisciplinary Management of Breast Cancer

Mark Pegram, MD, Stanford Women's Cancer Center;Charles A. Powell, MD, MBA, Mount Sinai-National Jewish Health Respiratory Institute;Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center
September 8th 2021

Key opinion leaders highlight the challenges inherent in using multidisciplinary care to manage breast cancer, particularly when a patient is seen at multiple institutions.

Multidisciplinary Care for a Patient With Metastatic HER2+ Breast Cancer

EP. 6: Multidisciplinary Care for a Patient With Metastatic HER2+ Breast Cancer

Mark Pegram, MD, Stanford Women's Cancer Center;Charles A. Powell, MD, MBA, Mount Sinai-National Jewish Health Respiratory Institute;Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center
September 8th 2021

An overview of optimal multidisciplinary care for a patient who presents with HER2+ metastatic breast cancer.

Breast Cancer Management: Monitoring Patients for ILD

EP. 7: Breast Cancer Management: Monitoring Patients for ILD

Mark Pegram, MD, Stanford Women's Cancer Center;Charles A. Powell, MD, MBA, Mount Sinai-National Jewish Health Respiratory Institute;Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center
September 15th 2021

In light of breast cancer therapies with the potential to cause interstitial lung disease, experts consider important patient risk factors and best monitoring practices.

Optimal Management of ILD in Patients With Breast Cancer

EP. 8: Optimal Management of ILD in Patients With Breast Cancer

Mark Pegram, MD, Stanford Women's Cancer Center;Charles A. Powell, MD, MBA, Mount Sinai-National Jewish Health Respiratory Institute;Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center
September 15th 2021

Shared insight on the optimal management of patients who develop interstitial lung disease while receiving therapy for breast cancer.

Practical Considerations for Identifying and Managing ILD in Breast Cancer

EP. 9: Practical Considerations for Identifying and Managing ILD in Breast Cancer

Mark Pegram, MD, Stanford Women's Cancer Center;Charles A. Powell, MD, MBA, Mount Sinai-National Jewish Health Respiratory Institute;Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center
September 22nd 2021

Drawing from personal experience, experts provide practical advice on identifying and treating interstitial lung disease in patients with breast cancer during the era of COVID-19.

Multidisciplinary Care in Breast Cancer: Take-Home Messages

EP. 10: Multidisciplinary Care in Breast Cancer: Take-Home Messages

Mark Pegram, MD, Stanford Women's Cancer Center;Charles A. Powell, MD, MBA, Mount Sinai-National Jewish Health Respiratory Institute;Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center
September 22nd 2021

Take-home messages regarding the optimal identification and management of ILD in breast cancer through the lens of multidisciplinary care.

Experts on ILD

EP. 11: An Overview of Interstitial Lung Disease

Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Mark Pegram, MD, Stanford Women's Cancer Center;Charles A. Powell, MD, MBA, Mount Sinai-National Jewish Health Respiratory Institute
September 24th 2021

Joyce A. O’Shaughnessy, MD, provides an overview of interstitial lung disease, considering both causes and possible risk factors.

Experts on Interstitial Lung Disease

EP. 12: Identifying ILD: Symptomology and Work-Up

Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Charles A. Powell, MD, MBA, Mount Sinai-National Jewish Health Respiratory Institute;Mark Pegram, MD, Stanford Women's Cancer Center
September 24th 2021

Comprehensive insight on the symptomology of interstitial lung disease, followed by tools and methods that can aid in accurate diagnosis.

Experts on Interstitial Lung Disease

EP. 13: Identifying Risk Factors for Interstitial Lung Disease

Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Mark Pegram, MD, Stanford Women's Cancer Center;Charles A. Powell, MD, MBA, Mount Sinai-National Jewish Health Respiratory Institute
October 1st 2021

A brief review of the full spectrum of risk factors that impact the likelihood of interstitial lung disease.

Experts on Interstitial Lung Disease

EP. 14: Monitoring Patients for Interstitial Lung Disease

Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Mark Pegram, MD, Stanford Women's Cancer Center;Charles A. Powell, MD, MBA, Mount Sinai-National Jewish Health Respiratory Institute
October 1st 2021

Experts discuss the optimal monitoring of patients to identify interstitial lung disease early and how to intervene.

Experts on Interstitial Lung Disease

EP. 15: Approaching the Management of Interstitial Lung Disease

Mark D. Pegram, MD;Charles Powell, MD;Joyce A. O'Shaughnessy, MD
October 8th 2021

Experts consider the mainstays in ILD management and factors that may dictate one treatment strategy over another.

Experts on Interstitial Lung Disease

EP. 16: Managing ILD: Taking Therapeutic Class Into Account

Mark D. Pegram, MD;Charles Powell, MD;Joyce A. O'Shaughnessy, MD
October 8th 2021

Brief considerations for the impact an agent’s therapeutic class can have on how interstitial lung disease should be approached.

Experts on Interstitial Lung Disease

EP. 17: Optimizing the Management of ILD: Steroids, Therapy Cessation, and Dose Modification

Mark D. Pegram, MD;Charles Powell, MD;Joyce A. O'Shaughnessy, MD
October 15th 2021

A broad review of strategies to manage interstitial lung disease, including steroid use, therapy cessation/rechallenging, and dose reduction.

Experts on Interstitial Lung Disease

EP. 18: Role of Bronchoscopy in Identifying and Managing ILD

Mark D. Pegram, MD;Charles Powell, MD;Joyce A. O'Shaughnessy, MD
October 15th 2021

Charles A. Powell, MD, MBA, leads a discussion on bronchoscopy’s role in identifying interstitial lung disease.

Experts on interstitial lung disease

EP. 19: Understanding the Risk-Benefit Comparison of Agents That May Cause ILD

Mark D. Pegram, MD;Charles Powell, MD;Joyce A. O'Shaughnessy
October 22nd 2021

Key opinion leaders share risk-benefit considerations when utilizing therapies that may increase a patient’s risk of developing ILD.

Experts on interstitial lung disease

EP. 20: Multidisciplinary Care in ILD Management: Role of a Pulmonologist

Mark D. Pegram, MD;Charles Powell, MD;Joyce A. O'Shaughnessy, MD
October 22nd 2021

Shared insight on the benefit of multidisciplinary care and the pulmonologist’s role in identifying and managing interstitial lung disease.

Experts on interstitial lung disease

EP. 21: Optimizing the Management of ILD: Take-Home Messages

Mark D. Pegram, MD;Charles Powell, MD;Joyce A. O'Shaughnessy
October 29th 2021

Experts highlight key messages regarding optimal identification and management of interstitial lung disease.

Latest Conference Coverage

Bexobrutideg Is Tolerable and Yields High Response Rates in Relapsed/Refractory Waldenström Macroglobulinemia

Axi-Cel, Liso-Cel, and Tisa-Cel Show Comparable Real-World Survival Outcomes in DLBCL

Pirtobrutinib Improves Patient-Reported Outcomes in Relapsed/Refractory CLL/SLL

MAIC Analysis Shows PFS Favorability With Zanubrutinib vs Acalabrutinib/Venetoclax in CLL

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

Download on Apple
© 2025 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact